{
    "clinical_study": {
        "@rank": "154568", 
        "arm_group": [
            {
                "arm_group_label": "Surfolase capsule & HT-002-01", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "HT-002-01 & Surfolase capsule", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Study to compare safety and pharmacokinetic properties of surfolase capsule and HT-002-01\n      after oral administration for one day in healthy male volunteer."
        }, 
        "brief_title": "Study To Compare Safety and Pharmacokinetic Properties of Surfolase Capsule and HT-002-01 in Healthy Male Volunteers", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. healthy male subjects between the age of 20 and 55 years with body mass index between\n             18.5 and 25\n\n          2. Volunteers without apriority of chronic disease\n\n          3. Volunteers must be in good health as determined by the investigator based on a\n             detailed medical history, full physical examination, electrocardiogram, laboratory\n             tests and urinalysis\n\n          4. Volunteers who comply with the protocol, understand and sign an informed consent\n\n        Exclusion Criteria:\n\n          1. Sensitive response to acebrophylline and xanthine\n\n          2. Galactose intolerance, Lapp lactase deficiency and Glucose-Galactose Malabsorption\n\n          3. Known history of renal, hepatic, respiratory, neurologic, endocrine, cardiac vascular\n             and hematopoietic disease, especially gallstone\n\n          4. Known history of gastrointestinal disease which affects the absorption of medicine.\n\n          5. Excluded by screening tests\n\n          6. Upper limit of AST, ALT>1.25 times Upper limit of total bilirubin>1.5 times\n\n          7. Estimated GFR<80mL/min/1.73m2)\n\n          8. systolic blood pressure < 90 or > 150, diastolic blood pressure <50 or >100\n\n          9. Known history of drug abuse\n\n         10. caffeine>5cups/day, alcohol>210g/week, 10 more cigarettes/day\n\n         11. Use of any prescription drug within 14days or over-the-counter (OTC) medication\n             within 7 days prior to dosing\n\n         12. Participation in any clinical investigation within 60 days prior to study start\n\n         13. Donation of blood within 60 days, donation of component blood within 30days\n\n         14. Judged by the investigators to be undesirable as subjects"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01723891", 
            "org_study_id": "HT-002-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Surfolase capsule & HT-002-01", 
                    "HT-002-01 & Surfolase capsule"
                ], 
                "intervention_name": "Surfolase capsule", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Surfolase capsule & HT-002-01", 
                    "HT-002-01 & Surfolase capsule"
                ], 
                "intervention_name": "HT-002-01", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "November 7, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Yonsei University Health System, Severance Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)"
        }, 
        "phase": "Phase 1", 
        "primary_outcome": {
            "measure": "AUCt, Cmax"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01723891"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "AUCinf, Tmax, t1/2"
        }, 
        "source": "Hyundai Pharmaceutical Co., LTD.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hyundai Pharmaceutical Co., LTD.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}